Original article
Long-term Safety and Efficacy of Etanercept in the Treatment of Psoriasis
Seguridad y eficacia de etanercept a largo plazo en el tratamiento de la psoriasis
V. Zaragoza
, A. Pérez, J.L. Sánchez, V. Oliver, L. Martínez, V. Alegre
Autor para correspondencia
Servicio de Dermatología, Consorcio Hospital General Universitario de Valencia, Valencia, Spain
Leído
5913
Vecesse ha leído el artículo
2548
Total PDF
3365
Total HTML
Compartir estadísticas
array:23 [ "pii" => "S1578219010705795" "issn" => "15782190" "doi" => "10.1016/S1578-2190(10)70579-5" "estado" => "S300" "fechaPublicacion" => "2010-01-01" "aid" => "70579" "copyright" => "Academia Española de Dermatología y Venereología and Elsevier España, S.L." "copyrightAnyo" => "2010" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2010;101:47-53" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2454 "formatos" => array:3 [ "EPUB" => 43 "HTML" => 1718 "PDF" => 693 ] ] "itemSiguiente" => array:18 [ "pii" => "S1578219010705801" "issn" => "15782190" "doi" => "10.1016/S1578-2190(10)70580-1" "estado" => "S300" "fechaPublicacion" => "2010-01-01" "aid" => "70580" "copyright" => "Academia Española de Dermatología y Venereología and Elsevier España, S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2010;101:54-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2537 "formatos" => array:3 [ "EPUB" => 38 "HTML" => 1511 "PDF" => 988 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Quinacrine in the Treatment of Cutaneous Lupus Erythematosus: Practical Aspects and a Case Series" "tienePdf" => "en" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "54" "paginaFinal" => "58" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Aspectos Prácticos de la Quinacrina Como Tratamiento del Lupus Eritematoso Cutáneo: Serie de Casos" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "B. González-Sixto, I. García-Doval, R. Oliveira, C. Posada, M.A. García-Cruz, M. Cruces" "autores" => array:6 [ 0 => array:2 [ "nombre" => "B." "apellidos" => "González-Sixto" ] 1 => array:2 [ "nombre" => "I." "apellidos" => "García-Doval" ] 2 => array:2 [ "nombre" => "R." "apellidos" => "Oliveira" ] 3 => array:2 [ "nombre" => "C." "apellidos" => "Posada" ] 4 => array:2 [ "nombre" => "M.A." "apellidos" => "García-Cruz" ] 5 => array:2 [ "nombre" => "M." "apellidos" => "Cruces" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219010705801?idApp=UINPBA000044" "url" => "/15782190/0000010100000001/v1_201304241512/S1578219010705801/v1_201304241512/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S1578219010705783" "issn" => "15782190" "doi" => "10.1016/S1578-2190(10)70578-3" "estado" => "S300" "fechaPublicacion" => "2010-01-01" "aid" => "70578" "copyright" => "Academia Española de Dermatología y Venereología and Elsevier España, S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2010;101:39-46" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2308 "formatos" => array:3 [ "EPUB" => 48 "HTML" => 1529 "PDF" => 731 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Changes in the Incidence of Skin Cancer Between 1978 and 2002" "tienePdf" => "en" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "39" "paginaFinal" => "46" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Evolución de la incidencia del cáncer de piel en el período 1978-2002" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P. Aceituno-Madera, A. Buendía-Eisman, S. Arias-Santiago, S. Serrano-Ortega" "autores" => array:4 [ 0 => array:2 [ "nombre" => "P." "apellidos" => "Aceituno-Madera" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Buendía-Eisman" ] 2 => array:2 [ "nombre" => "S." "apellidos" => "Arias-Santiago" ] 3 => array:2 [ "nombre" => "S." "apellidos" => "Serrano-Ortega" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219010705783?idApp=UINPBA000044" "url" => "/15782190/0000010100000001/v1_201304241512/S1578219010705783/v1_201304241512/en/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Long-term Safety and Efficacy of Etanercept in the Treatment of Psoriasis" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "47" "paginaFinal" => "53" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "V. Zaragoza, A. Pérez, J.L. Sánchez, V. Oliver, L. Martínez, V. Alegre" "autores" => array:6 [ 0 => array:4 [ "nombre" => "V." "apellidos" => "Zaragoza" "email" => array:1 [ 0 => "vioz@comv.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor1" ] ] ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Pérez" ] 2 => array:2 [ "nombre" => "J.L." "apellidos" => "Sánchez" ] 3 => array:2 [ "nombre" => "V." "apellidos" => "Oliver" ] 4 => array:2 [ "nombre" => "L." "apellidos" => "Martínez" ] 5 => array:2 [ "nombre" => "V." "apellidos" => "Alegre" ] ] "afiliaciones" => array:1 [ 0 => array:1 [ "entidad" => "Servicio de Dermatología, Consorcio Hospital General Universitario de Valencia, Valencia, Spain" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Seguridad y eficacia de etanercept a largo plazo en el tratamiento de la psoriasis" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2008-10-27" "fechaAceptado" => "2009-07-09" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec84653" "palabras" => array:4 [ 0 => "Etanercept" 1 => "Long-term treatment" 2 => "Safety" 3 => "Efficacy" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec84652" "palabras" => array:4 [ 0 => "Etanercept" 1 => "Tratamiento a largo plazo" 2 => "Seguridad" 3 => "Eficacia" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span class="elsevierStyleSectionTitle">Background</span><p class="elsevierStyleSimplePara elsevierViewall">Clinical experience has shown that, in patients with psoriasis, suspending treatment with etanercept at week 24, as indicated in the prescribing information, may lead to a rebound effect. Several clinical trials support long-term use of etanercept, which was shown to have a good safety and efficacy profile.</p> <span class="elsevierStyleSectionTitle">Material and methods</span><p class="elsevierStyleSimplePara elsevierViewall">This was a retrospective, observational study of 43 patients with moderate to severe plaque psoriasis, with and without joint involvement, who received continuous treatment with etanercept for more than 24 weeks.</p> <span class="elsevierStyleSectionTitle">Results</span><p class="elsevierStyleSimplePara elsevierViewall">Etanercept was administered for a mean of 57 weeks. Overall, the Psoriasis Area and Severity Index (PASI) score decreased from a baseline value of 22.5 to 4.3 after treatment. In addition, with continuous treatment, most patients maintained decreases in PASI scores of 50% and even of 75%. Some patients without significant improvement in their PASI score in the first 24 weeks did manage to achieve significant results after prolonged treatment. These outcomes were achieved with a low incidence of adverse effects (reported in 13 patients [30.2%]), which were generally mild.</p> <span class="elsevierStyleSectionTitle">Conclusions</span><p class="elsevierStyleSimplePara elsevierViewall">We present our clinical experience with long-term etanercept treatment in patients with moderate to severe psoriasis, with and without associated joint involvement. The efficacy and safety profiles were found to be favorable.</p>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span class="elsevierStyleSectionTitle">Introducción</span><p class="elsevierStyleSimplePara elsevierViewall">La experiencia clínica demuestra que la suspensión del tratamiento con etanercept en pacientes con psoriasis en la semana 24, como indica la ficha técnica del fármaco, produce en algunos casos rebrote de la enfermedad. Existen diversos ensayos que avalan el uso de etanercept a largo plazo con un buen perfil de seguridad y eficacia.</p> <span class="elsevierStyleSectionTitle">Material y métodos</span><p class="elsevierStyleSimplePara elsevierViewall">Estudio observacional, retrospectivo, en el que se recogió a 43 pacientes con psoriasis en placas de moderada a grave, con y sin artropatía, tratados con etanercept de forma continua durante más de 24 semanas.</p> <span class="elsevierStyleSectionTitle">Resultados</span><p class="elsevierStyleSimplePara elsevierViewall">El etanercept se administró durante un tiempo promedio de 57 semanas, y disminuyó el PASI (Psoriasis Area Severity Index) de forma global de un valor basal de 22,5 a 4,3. Además, con el tratamiento continuo, la mayor parte de los pacientes mantuvieron puntuaciones PASI inferiores al 50% o incluso al 75%. Por otra parte, algunos pacientes que no alcanzaron mejorías significativas en su puntuación PASI en las primeras 24 semanas pueden conseguirlo prolongando el tratamiento. Todo ello con una baja incidencia de efectos adversos (13 pacientes [30,2%]) y de características leves.</p> <span class="elsevierStyleSectionTitle">Conclusiones</span><p class="elsevierStyleSimplePara elsevierViewall">Exponemos nuestra experiencia clínica con el tratamiento con etanercept a largo plazo en pacientes con psoriasis de moderada a grave, con y sin artropatía asociada, y demostramos un perfil favorable de eficacia y seguridad.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:21 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence of psoriasis in Spain (Epiderma Project: phase I)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C. Ferrandiz" 1 => "X. Bordas" 2 => "V. García-Patos" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2001" "volumen" => "15" "paginaInicial" => "20" "paginaFinal" => "23" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11451315" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Eficacia clínica del etanercept en psoriasis y artritis psoriásica" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "E. Herrera" 1 => "S. Habicheyn" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2005" "volumen" => "96" "paginaInicial" => "10" "paginaFinal" => "24" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: An updated review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Romero-Maté" 1 => "C. García-Donoso" 2 => "S. Córdoba-Guijarro" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Clin Dermatol" "fecha" => "2007" "volumen" => "8" "paginaInicial" => "143" "paginaFinal" => "155" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17492843" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A randomized trial of etanercept as monotherapy for psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.B. Gottlieb" 1 => "R.T. Matheson" 2 => "N. Lowe" 3 => "G.G. Krueger" 4 => "S. Kang" 5 => "B.S. Goffe" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archderm.139.12.1627" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2003" "volumen" => "139" "paginaInicial" => "1627" "paginaFinal" => "1632" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14676082" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "P.J. Mease" 1 => "B.S. Goffe" 2 => "J. Metz" 3 => "A. VanderStoep" 4 => "B. Finck" 5 => "D.J. Burge" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(00)02530-7" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2000" "volumen" => "356" "paginaInicial" => "385" "paginaFinal" => "390" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10972371" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etanercept as monotherapy in patients with psoriasis" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "Etanercept Psoriasis Study Group" "etal" => true "autores" => array:6 [ 0 => "C.L. Leonardi" 1 => "J.L. Powers" 2 => "R.T. Matheson" 3 => "B.S. Goffe" 4 => "R. Zitnik" 5 => "A. Wang" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "N Engl J Med" "fecha" => "2003" "volumen" => "3" "paginaInicial" => "2014" "paginaFinal" => "2022" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A global phase II randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "Etanercept Psoriasis Study Group" "etal" => true "autores" => array:6 [ 0 => "K.A. Papp" 1 => "S. Tyring" 2 => "M. Lahfa" 3 => "J. Prinz" 4 => "C.E. Griffiths" 5 => "A.M. Nakanishi" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2005" "volumen" => "1" "paginaInicial" => "1304" "paginaFinal" => "1312" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Wyeth. Ficha técnica de Enbrel®. Spain; 2005." ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recommendations for the use of etanercept in psoriasis: A European dermatology expert group consensus" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "European Dermatology Expert Group" "etal" => true "autores" => array:6 [ 0 => "W.H. Boehncke" 1 => "R.A. Brasie" 2 => "J. Barker" 3 => "S. Chimenti" 4 => "E. Daudén" 5 => "M. de Rie" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-3083.2006.01707.x" "Revista" => array:6 [ "tituloSerie" => "JEADV" "fecha" => "2006" "volumen" => "20" "paginaInicial" => "988" "paginaFinal" => "998" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16922950" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The long-term efficacy and safety of new biological therapies for psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "K.A. Papp" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00403-006-0660-6" "Revista" => array:7 [ "tituloSerie" => "Arch Dermatol Res" "fecha" => "2006" "volumen" => "298" "paginaInicial" => "7" "paginaFinal" => "15" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16691429" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0016508511000849" "estado" => "S300" "issn" => "00165085" ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "G.G. Krueger" 1 => "B. Elewski" 2 => "K.A. Papp" 3 => "A. Wang" 4 => "R. Zitnik" 5 => "A. Jahreis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2005.10.054" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2006" "volumen" => "54" "paginaInicial" => "S112" "paginaFinal" => "S119" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16488321" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etanercept 50mg once weekly sustains safety and efficacy for up to 96 weeks in plaque psoriasis patient (poster)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "B. Elewski" 1 => "B. Strober" 2 => "S. Tyring" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "15th Congress of the European Academy of Dermatology and Venereology" "conferencia" => "Rhodes" "serieFecha" => "2006" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etanercept dose escalation to 50mg twice weekly sustains safety and efficacy for up to 48 weeks in psoriasis patients who had incomplete response to 50mg once weekly (poster)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "B. Elewski" 1 => "C. Leonardi" 2 => "A. Gottlieb" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "15th Congress of the European Academy of Dermatology and Venereology" "conferencia" => "Rhodes" "serieFecha" => "2006" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sustained long-term clinical efficacy and safety for up to 2,5 years of etanercept in patients with psoriasis (poster)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "B. Elewski" 1 => "C. Leonardi" 2 => "A. Gottlieb" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "64th Annual Meeting of the American Academy of Dermatology" "conferencia" => "San Francisco (CA)" "serieFecha" => "2006" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term patient-reported outcomes: Etanercept therapy in patients with psoriasis (poster)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "C.E.M. Griffiths" 1 => "K. Papp" 2 => "J. Koo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "64th Annual Meeting of the American Academy of Dermatology" "conferencia" => "San Francisco (CA)" "serieFecha" => "2006" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evaluation of clinical efficacy of etanercept at two different dosages with and without interruption in patients with moderate to severe plaque psoriasis (poster)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "B. Elewski" 1 => "C. Leonardi" 2 => "P. Van de Kerkhof" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "15th Congress of the European Academy of Dermatology and Venereology" "conferencia" => "Rhodes" "serieFecha" => "2006" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A 96-week phase 3 study of safety and efficacy of etanercept 50mg twice weekly in patients with psoriasis (poster)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S. Tyring" 1 => "Y. Poulin" 2 => "R. Langley" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "64th Annual Meeting of the American Academy of Dermatology" "conferencia" => "San Francisco (CA)" "serieFecha" => "2006" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Terapia biológica y psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "R. Gamo" 1 => "J.L. López-Estebaranz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2006" "volumen" => "97" "paginaInicial" => "1" "paginaFinal" => "17" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16540046" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etanercept en la psoriasis. Experiencia clínica" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:1 [ 0 => "B. Martín" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2008" "volumen" => "9" "paginaInicial" => "540" "paginaFinal" => "545" ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis (poster)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M. Lebwohl" 1 => "A. Gottlieb" 2 => "W. Wallis" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "63rd Annual Meeting of the American Academy of Dermatology" "conferencia" => "New Orleans (LA)" "serieFecha" => "2007" ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety and efficacy of up to 9 years of etanercept therapy in North American patients with rheumatoid arthritis (poster)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M.E. Weinblatt" 1 => "M.C. Genovese" 2 => "L.W. Moreland" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "65th Annual Meeting of the American Academy of Dermatology" "conferencia" => "Washington, DC" "serieFecha" => "2007" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010100000001/v1_201304241512/S1578219010705795/v1_201304241512/en/main.assets" "Apartado" => array:4 [ "identificador" => "6155" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original Articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010100000001/v1_201304241512/S1578219010705795/v1_201304241512/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219010705795?idApp=UINPBA000044" ]
| año/Mes | Html | Total | |
|---|---|---|---|
| 2024 Noviembre | 7 | 8 | 15 |
| 2024 Octubre | 58 | 43 | 101 |
| 2024 Septiembre | 58 | 33 | 91 |
| 2024 Agosto | 76 | 75 | 151 |
| 2024 Julio | 53 | 38 | 91 |
| 2024 Junio | 52 | 33 | 85 |
| 2024 Mayo | 41 | 33 | 74 |
| 2024 Abril | 48 | 25 | 73 |
| 2024 Marzo | 47 | 43 | 90 |
| 2024 Febrero | 40 | 39 | 79 |
| 2024 Enero | 34 | 54 | 88 |
| 2023 Diciembre | 39 | 24 | 63 |
| 2023 Noviembre | 41 | 30 | 71 |
| 2023 Octubre | 51 | 34 | 85 |
| 2023 Septiembre | 30 | 35 | 65 |
| 2023 Agosto | 28 | 25 | 53 |
| 2023 Julio | 30 | 50 | 80 |
| 2023 Junio | 36 | 26 | 62 |
| 2023 Mayo | 30 | 23 | 53 |
| 2023 Abril | 27 | 19 | 46 |
| 2023 Marzo | 24 | 20 | 44 |
| 2023 Febrero | 18 | 23 | 41 |
| 2023 Enero | 26 | 33 | 59 |
| 2022 Diciembre | 24 | 31 | 55 |
| 2022 Noviembre | 12 | 26 | 38 |
| 2022 Octubre | 9 | 14 | 23 |
| 2022 Septiembre | 13 | 49 | 62 |
| 2022 Agosto | 17 | 64 | 81 |
| 2022 Julio | 10 | 59 | 69 |
| 2022 Junio | 12 | 37 | 49 |
| 2022 Mayo | 14 | 42 | 56 |
| 2022 Abril | 19 | 32 | 51 |
| 2022 Marzo | 17 | 46 | 63 |
| 2022 Febrero | 15 | 30 | 45 |
| 2022 Enero | 17 | 37 | 54 |
| 2021 Diciembre | 17 | 43 | 60 |
| 2021 Noviembre | 29 | 53 | 82 |
| 2021 Octubre | 23 | 51 | 74 |
| 2021 Septiembre | 20 | 49 | 69 |
| 2021 Agosto | 20 | 32 | 52 |
| 2021 Julio | 19 | 18 | 37 |
| 2021 Junio | 16 | 35 | 51 |
| 2021 Mayo | 16 | 24 | 40 |
| 2021 Abril | 33 | 53 | 86 |
| 2021 Marzo | 57 | 18 | 75 |
| 2021 Febrero | 61 | 37 | 98 |
| 2021 Enero | 44 | 23 | 67 |
| 2020 Diciembre | 30 | 17 | 47 |
| 2020 Noviembre | 22 | 20 | 42 |
| 2020 Octubre | 19 | 11 | 30 |
| 2020 Septiembre | 29 | 16 | 45 |
| 2020 Agosto | 21 | 20 | 41 |
| 2020 Julio | 23 | 17 | 40 |
| 2020 Junio | 25 | 25 | 50 |
| 2020 Mayo | 16 | 15 | 31 |
| 2020 Abril | 16 | 16 | 32 |
| 2020 Marzo | 17 | 24 | 41 |
| 2020 Febrero | 1 | 5 | 6 |
| 2020 Enero | 0 | 4 | 4 |
| 2019 Diciembre | 0 | 4 | 4 |
| 2019 Noviembre | 0 | 1 | 1 |
| 2019 Octubre | 0 | 3 | 3 |
| 2019 Septiembre | 0 | 2 | 2 |
| 2019 Agosto | 0 | 2 | 2 |
| 2019 Julio | 0 | 6 | 6 |
| 2019 Junio | 0 | 17 | 17 |
| 2019 Mayo | 0 | 53 | 53 |
| 2019 Marzo | 0 | 2 | 2 |
| 2019 Febrero | 0 | 3 | 3 |
| 2018 Marzo | 0 | 1 | 1 |
| 2018 Febrero | 11 | 4 | 15 |
| 2018 Enero | 13 | 6 | 19 |
| 2017 Diciembre | 15 | 6 | 21 |
| 2017 Noviembre | 17 | 3 | 20 |
| 2017 Octubre | 14 | 2 | 16 |
| 2017 Septiembre | 27 | 5 | 32 |
| 2017 Agosto | 51 | 7 | 58 |
| 2017 Julio | 49 | 10 | 59 |
| 2017 Junio | 65 | 25 | 90 |
| 2017 Mayo | 42 | 11 | 53 |
| 2017 Abril | 27 | 10 | 37 |
| 2017 Marzo | 29 | 8 | 37 |
| 2017 Febrero | 18 | 4 | 22 |
| 2017 Enero | 16 | 4 | 20 |
| 2016 Diciembre | 26 | 11 | 37 |
| 2016 Noviembre | 28 | 6 | 34 |
| 2016 Octubre | 29 | 16 | 45 |
| 2016 Septiembre | 34 | 6 | 40 |
| 2016 Agosto | 39 | 7 | 46 |
| 2016 Julio | 36 | 4 | 40 |
| 2016 Junio | 6 | 10 | 16 |
| 2016 Mayo | 6 | 4 | 10 |
| 2016 Abril | 6 | 3 | 9 |
| 2016 Marzo | 5 | 9 | 14 |
| 2016 Febrero | 8 | 3 | 11 |
| 2016 Enero | 12 | 0 | 12 |
| 2015 Diciembre | 15 | 0 | 15 |
| 2015 Noviembre | 13 | 3 | 16 |
| 2015 Octubre | 13 | 0 | 13 |
| 2015 Septiembre | 10 | 3 | 13 |
| 2015 Agosto | 15 | 3 | 18 |
| 2015 Julio | 29 | 9 | 38 |
| 2015 Junio | 42 | 6 | 48 |
| 2015 Mayo | 74 | 13 | 87 |
| 2015 Abril | 47 | 9 | 56 |
| 2015 Marzo | 46 | 5 | 51 |
| 2015 Febrero | 36 | 9 | 45 |
| 2015 Enero | 29 | 14 | 43 |
| 2014 Diciembre | 21 | 6 | 27 |
| 2014 Noviembre | 25 | 10 | 35 |
| 2014 Octubre | 36 | 10 | 46 |
| 2014 Septiembre | 30 | 15 | 45 |
| 2014 Agosto | 31 | 11 | 42 |
| 2014 Julio | 34 | 15 | 49 |
| 2014 Junio | 34 | 9 | 43 |
| 2014 Mayo | 38 | 13 | 51 |
| 2014 Abril | 35 | 7 | 42 |
| 2014 Marzo | 59 | 13 | 72 |
| 2014 Febrero | 27 | 14 | 41 |
| 2014 Enero | 33 | 11 | 44 |
| 2013 Diciembre | 46 | 10 | 56 |
| 2013 Noviembre | 27 | 16 | 43 |
| 2013 Octubre | 31 | 15 | 46 |
| 2013 Septiembre | 24 | 16 | 40 |
| 2013 Agosto | 34 | 28 | 62 |
| 2013 Julio | 43 | 23 | 66 |
| 2013 Junio | 25 | 24 | 49 |
| 2013 Mayo | 25 | 20 | 45 |
| 2013 Abril | 18 | 19 | 37 |
| 2013 Marzo | 28 | 21 | 49 |
| 2013 Febrero | 16 | 11 | 27 |
Mostrar todo
